Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul 11;40(7):714-716.
doi: 10.1016/j.ccell.2022.05.017. Epub 2022 Jun 16.

Innate-like T cells: A promising asset in anti-cancer immunity

Martina Molgora  1 , Marco Colonna  2
Affiliations
Comment

Innate-like T cells: A promising asset in anti-cancer immunity

Martina Molgora et al. Cancer Cell. .

Abstract

In Nature, Chou et al. identify a subset of innate-like αβ T cells with high cytotoxic potential that accumulate in tumors and elicit an anti-tumor response. Given their capacity to maintain an activation state without undergoing exhaustion, these innate-like T cells may represent effective therapeutic agents for cell-based approaches.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Marco Colonna is a member of the NGM Biopharmaceutical scientific advisory board and receives research grants from Oncorus and NGM Biopharmaceutical. Martina Molgora declares no competing interests.

Figures

Figure 1.
Figure 1.. Identification of ILTCK origin and function.
Thymic progenitors give rise to both conventional (CD8+ and CD4+) and innate-like T cell subsets (CD8αα ILTCKs, CD8αα IELs, CD4− CD8− T cells, γδ T cells, iNKT and MAIT). Intratumoral ILTCKs have been identified in breast, prostate and colorectal cancer and shown to accumulate in response to tumor-derived IL-15. ILTCKs express markers of innate lymphocytes and are highly cytotoxic. ILTCKs, as well as CD8αα IELs, derive from CD122+PD1+ thymic progenitors in a TCR-dependent manner.
See this image and copyright information in PMC

Comment on

  • Programme of self-reactive innate-like T cell-mediated cancer immunity.
    Chou C, Zhang X, Krishna C, Nixon BG, Dadi S, Capistrano KJ, Kansler ER, Steele M, Han J, Shyu A, Zhang J, Stamatiades EG, Liu M, Li S, Do MH, Edwards C, Kang DS, Chen CT, Wei IH, Pappou EP, Weiser MR, Garcia-Aguilar J, Smith JJ, Leslie CS, Li MO. Chou C, et al. Nature. 2022 May;605(7908):139-145. doi: 10.1038/s41586-022-04632-1. Epub 2022 Apr 20. Nature. 2022. PMID: 35444279 Free PMC article.

References

    1. Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, Schietinger A, Schumacher TN, Schwartzberg PL, Sharpe AH, Speiser DE, Wherry EJ, Youngblood BA, and Zehn D (2019). Defining ‘T cell exhaustion’ Nat. Rev. Immunol 11, 665–674. - PMC - PubMed
    1. Chou C, Zhang X, Krishna C, Nixon BG, Dadi S, Capistrano KJ, Kansler ER, Steele M, Han J, Shyu A, Zhang J, Stamatiades EG, Liu M, Li S, Do MH, Edwards C, Kang DS, Chen C, Wei IH, Pappou EP, Weiser MR, Garcia-Aguilar J, Smith JJ, Leslie CS, and Li MO (2022). Programme of self-reactive innate-like T cell-mediated cancer immunity. Nature. 605, 139–145. - PMC - PubMed
    1. Dadi S, Chhangawala S, Whitlock BM, Franklin RA, Luo CT, Oh SA, Toure A, Pritykin Y, Huse M, Leslie CS, and Li MO (2016). Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells. Cell. 164, 365–377. - PMC - PubMed
    1. Ponzetta A, Carriero R, Carnevale S, Barbagallo M, Molgora M, Perucchini C, Magrini E, Gianni F, Kunderfranco P, Polentarutti N, Pasqualini F, Di Marco S, Supino D, Peano C, Cananzi F, Colombo P, Pilotti S, Alomar SY, Bonavita E, Galdiero MR, Garlanda C, Mantovani A, and Jaillon S Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors. (2019). Cell. 178, 346–360. - PMC - PubMed
    1. Schumacher TN, and Schreiber RD (2015). Neoantigens in cancer immunotherapy. Science 348, 69–74. - PubMed

Publication types